BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia-Reference-Cited by-同舟云学术

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia

Published:2010-05 Issue:3 Volume:149 Page:458-460
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Lucas Claire M.,Harris Robert J.,Giannoudis Athina,Knight Katy,Watmough Sarah J.,Clark Richard E.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2009.08066.x/fullpdf

Reference9 articles.

1. Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters;Davies;Leukemia,2009

2. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance;Kantarjian;Blood,2007

3. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis;de Lavallade;Journal of Clinical Oncology,2008

4. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials;Lucas;Leukemia,2008

5. Chronic myeloid leukaemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib than e14a2 patients;Lucas;Haematologica,2009

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRKL but not CRKII contributes to hemin‐induced erythroid differentiation of CML;Journal of Cellular and Molecular Medicine;2024-04-29

2. In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile;2023-10-12

3. Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib;Blood Cancer Journal;2023-09-11

4. Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity;Frontiers in Oncology;2022-06-08

5. Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia;Cancers;2021-05-12